Atara Biotherapeutics Inc’s (ATRA) Stock: A -10.91% Simple Moving Average for the Past 20 Days

ABT Stock

The stock of Atara Biotherapeutics Inc (ATRA) has seen a -19.23% decrease in the past week, with a -21.59% drop in the past month, and a -26.36% decrease in the past quarter. The volatility ratio for the week is 10.65%, and the volatility levels for the past 30 days are at 11.36% for ATRA.. The simple moving average for the past 20 days is -10.91% for ATRA’s stock, with a -39.56% simple moving average for the past 200 days.

Is It Worth Investing in Atara Biotherapeutics Inc (NASDAQ: ATRA) Right Now?

ATRA has 36-month beta value of 0.55. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for ATRA is 98.32M, and currently, short sellers hold a 11.81% ratio of that float. The average trading volume of ATRA on May 30, 2024 was 1.63M shares.

ATRA) stock’s latest price update

Atara Biotherapeutics Inc (NASDAQ: ATRA) has experienced a decline in its stock price by -8.42 compared to its previous closing price of 0.61. However, the company has seen a fall of -19.23% in its stock price over the last five trading days. businesswire.com reported 2024-05-29 that THOUSAND OAKS, Calif.–(BUSINESS WIRE)—- $ATRA #CART–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases. Findings demon.

Analysts’ Opinion of ATRA

Many brokerage firms have already submitted their reports for ATRA stocks, with Mizuho repeating the rating for ATRA by listing it as a “Neutral.” The predicted price for ATRA in the upcoming period, according to Mizuho is $1 based on the research report published on November 09, 2023 of the previous year 2023.

ATRA Trading at -16.90% from the 50-Day Moving Average

After a stumble in the market that brought ATRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.91% of loss for the given period.

Volatility was left at 11.36%, however, over the last 30 days, the volatility rate increased by 10.65%, as shares sank -18.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.98% lower at present.

During the last 5 trading sessions, ATRA fell by -19.23%, which changed the moving average for the period of 200-days by -73.21% in comparison to the 20-day moving average, which settled at $0.6221. In addition, Atara Biotherapeutics Inc saw 9.20% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ATRA starting from Touchon Pascal, who sale 81,506 shares at the price of $0.62 back on May 16 ’24. After this action, Touchon Pascal now owns 1,829,146 shares of Atara Biotherapeutics Inc, valued at $50,289 using the latest closing price.

Nguyen AnhCo, the EVP, Chief Sci. & Tech Officer of Atara Biotherapeutics Inc, sale 42,899 shares at $0.62 during a trade that took place back on May 16 ’24, which means that Nguyen AnhCo is holding 898,498 shares at $26,469 based on the most recent closing price.

Stock Fundamentals for ATRA

Current profitability levels for the company are sitting at:

  • -6.36 for the present operating margin
  • 0.69 for the gross margin

The net margin for Atara Biotherapeutics Inc stands at -6.72. The total capital return value is set at 14.32. Equity return is now at value -2014.86, with -99.76 for asset returns.

Based on Atara Biotherapeutics Inc (ATRA), the company’s capital structure generated -1.04 points at debt to capital in total, while cash flow to debt ratio is standing at -3.67. The debt to equity ratio resting at -0.51. The interest coverage ratio of the stock is -43.28.

Currently, EBITDA for the company is -264.45 million with net debt to EBITDA at -0.27. When we switch over and look at the enterprise to sales, we see a ratio of 3.59. The receivables turnover for the company is 0.96for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.59.

Conclusion

To put it simply, Atara Biotherapeutics Inc (ATRA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts